

Who is eligible to participate in this study?

To be eligible to participate in the CHAMPION aHUS-312 Study:

- ✓ Diagnosis: a confirmed diagnosis of aHUS
- ✓ Age: from newborn to 18 years old, weighing at least 5kg (11lbs)
- ✓ Evidence of damage caused by uncontrolled complement, TMA (thrombotic microangiopathy) including:
 - Lab tests that show reduced kidney function, platelets and increased LDH (lactate dehydrogenase) indicating the destruction of red blood cells or hemolysis

Participants cannot have been treated before with eculizumab (or a drug that has a similar way of working).

**For more information about the CHAMPION 312 Study,
and for a detailed listing of eligibility criteria
please see clinicaltrials.gov #NCT03131219
or contact Alexion at clinicaltrials@alexion.com**